Paxil CRparoxetine

According to the FDA label: PAXIL CR is indicated in adults for the treatment of: Major depressive disorder (MDD) Panic disorder (PD) Social anxiety disorder (SAD) Premenstrual dysphoric disorder (PMDD) PAXIL CR is a selective serotonin reuptake inhibitor (SSRI) indicated for use in adults for the treatment of ( 1 ): Major Depressive Disorder (MDD) Panic Disorder (PD) Social Anxiety Disorder (SAD) Premenstrual Dysphoric Disorder (PMDD)

58,170 adverse event reports submitted to the FDA (1998–2026)

This data reflects voluntary reports submitted to the FDA's Adverse Event Monitoring System (AEMS), formerly the FDA Adverse Event Reporting System (FAERS). A report does not mean the medication caused the event. Data may be incomplete or contain errors. Learn more about AEMS. New to this data? Read our guide on how to interpret FDA adverse event reports →
New to FDA adverse event data? Here's how to read these reports →

Top Reported Adverse Events

The most frequently reported events in association with Paxil CR in the FAERS database. These are events reported by patients taking this medication, not necessarily caused by it. A single report may include multiple events.

Show these terms with plain-language definitions

Tap any term below for a plain-language definition.

Browse the full glossary →

Ranked by frequency of reports, not severity. The most-reported event is not necessarily the most dangerous or the most common in patients taking this drug.

Who Is Reporting

Demographics of patients in FAERS reports that included this information. Not all reports include patient demographics.

By Sex

View reporter sex data as a table
Paxil CR adverse event reports by reporter sex
SexReports
Female36,370
Male17,781
Unknown143

By Age Group

View age group data as a table
Paxil CR adverse event reports by reporter age group
Age groupReports
0-171,590
18-344,614
35-497,500
50-649,250
65-744,597
75+3,742

This shows who filed reports, reflecting who takes this drug and who tends to report, not who is at greatest risk.

Reported Outcomes

Outcomes recorded in FAERS reports that included Paxil CR. A single report may involve multiple reactions, each with a different outcome. These categories are defined by FDA reporting guidelines, not by PillSignal.

View outcome data as a table
Paxil CR adverse event reports by reported outcome
OutcomeReports
Non-Serious22,968
Other Serious20,759
Hospitalization15,059
Death3,669
Life-Threatening2,035
Disability1,936

Serious outcomes are far more likely to be reported than mild ones, so this overstates how often outcomes are serious. A recorded death does not mean the drug caused it.

Number of FAERS reports received per quarter for Paxil CR. Changes in volume may reflect shifts in prescribing rates, media attention, or reporting behavior, not changes in the medication's safety profile.

View report trend as a table
Paxil CR adverse event reports by year
YearReports
19982
20034
20046,693
20056,081
20064,741
20072,990
20082,730
20092,645
20103,015
20113,115
20122,883
20131,735
20141,759
20153,466
20163,111
20171,935
20181,700
20191,713
20201,493
20211,365
20221,290
20231,169
20241,206
20251,092
2026 (partial)237

The steep increase around 2004 reflects the FDA's move to electronic submission, not a change in this drug's safety. Trends track reporting volume, not risk.

Medications commonly reported with Paxil CR

In FDA adverse event reports that mention Paxil CR, these medications appeared most often in the same report.

This reflects co-occurrence in submitted reports, not evidence of drug interaction or combined risk. People often report several medications taken for the same condition or for unrelated reasons. Talk to a doctor or pharmacist about your specific medications.

Other medications with similar adverse event profiles in FDA FAERS reports.

Data Source

This data is sourced from the FDA's Adverse Event Monitoring System (AEMS), formerly FAERS, via the OpenFDA API. PillSignal is not affiliated with the FDA.

View this data on the FDA website →

Data last updated: June 2026